Top

Published in:

01-04-2021 | Magnetic Resonance Imaging | Gastrointestinal

The diagnostic performance of a simulated “short” gadoxetic acid-enhanced MRI protocol is similar to that of a conventional protocol for the detection of colorectal liver metastases

Authors: Camille Ghorra, Romain Pommier, Arthur Piveteau, Laura Rubbia-Brandt, Valérie Vilgrain, Sylvain Terraz, Maxime Ronot

Published in: European Radiology | Issue 4/2021

Abstract

Objectives

To compare the performance of standard and simulated short gadoxetic acid-enhanced MRI protocols for the detection of colorectal liver metastases (CRLM).

Methods

From 2008 to 2017, 67 patients (44 men (66%); mean age 65 ± 11 years old) who underwent gadoxetic acid-enhanced MRI during the initial work-up for colorectal cancer were included. Exams were independently reviewed by two readers blinded to clinical data in two reading sessions: (1) all acquired sequences (standard “long” protocol) and (2) only T2-weighted, diffusion-weighted, and hepatobiliary phase images (simulated “short” protocol). Readers characterized detected lesions using a 5-point scale (1—certainly benign to 5—certainly malignant). A lesion was considered a CRLM when the score was ≥ 3. The reference standard was histopathology or 12-month imaging follow-up. Chi-square, Student’s t, and McNemar tests were used for comparisons.

Results

A total of 486 lesions including 331 metastases (68%) were analyzed. The metastasis detection rate was 86.1% (95% CI 82–89.4)–86.7% (82.6–90) and 85.8% (81.6–89.2)–87% (82.9–90.2) with the short and long protocols, respectively (p > 0.99). Among detected lesions, 92.1% (89.1–94.4)–94.8% (92.2–96.6) and 84.6% (80.8–87.7)–88.8% (85.4–91.5) were correctly classified with the short and long protocols, respectively (p = 0.13 and p = 0.10). The results remained unchanged when lesions scored ≥ 4 were considered as CRLM.

Conclusion

The diagnostic performance of a simulated short gadoxetic enhanced-MR protocol including T2-weighted, diffusion-weighted, and hepatobiliary phase appears similar to that of a standard long protocol including dynamic phase images. Since this protocol shortens the duration of MR examination, it could facilitate the evaluation of patients with colorectal liver metastases.

Key Points

• The detection rate of colorectal metastases with a simulated, short, MRI protocol was similar to that of a standard protocol.

• The performance of both protocols for the differentiation of metastases and benign lesions appears to be similar.

• A short MR imaging protocol could facilitate the evaluation of patients with colorectal liver metastases.

Haggar FA, Boushey RP (2009) Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 22:191–197CrossRef

Boyle P, Langman JS (2000) ABC of colorectal cancer: epidemiology. BMJ 321:805–808CrossRef

Boyle P, Ferlay J (2005) Mortality and survival in breast and colorectal cancer. Nat Clin Pract Oncol 2:424–425CrossRef

Wale A, Van Cutsem E, Rao S, Cunningham D, Brown G (2018) Session 2: synchronous metastatic disease-liver first or primary first? The oncologist decides. Colorectal Dis 20(Suppl 1):52–55CrossRef

Adam R, De Gramont A, Figueras J et al (2012) The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 17:1225–1239CrossRef

Mainenti PP, Romano F, Pizzuti L et al (2015) Non-invasive diagnostic imaging of colorectal liver metastases. World J Radiol 7:157–169CrossRef

Niekel MC, Bipat S, Stoker J (2010) Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 257:674–684CrossRef

Cho JY, Lee YJ, Han H-S et al (2015) Role of gadoxetic acid-enhanced magnetic resonance imaging in the preoperative evaluation of small hepatic lesions in patients with colorectal cancer. World J Surg 39:1161–1166CrossRef

Kim HJ, Lee SS, Byun JH et al (2015) Incremental value of liver MR imaging in patients with potentially curable colorectal hepatic metastasis detected at CT: a prospective comparison of diffusion-weighted imaging, gadoxetic acid-enhanced MR imaging, and a combination of both MR techniques. Radiology 274:712–722CrossRef

10.

Floriani I, Torri V, Rulli E et al (2010) Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging 31:19–31CrossRef

11.

Tsurusaki M, Sofue K, Murakami T (2016) Current evidence for the diagnostic value of gadoxetic acid-enhanced magnetic resonance imaging for liver metastasis. Hepatol Res 46:853–861CrossRef

12.

Jeong HT, Kim M-J, Park M-S et al (2012) Detection of liver metastases using gadoxetic-enhanced dynamic and 10- and 20-minute delayed phase MR imaging. J Magn Reson Imaging 35:635–643CrossRef

13.

Costa EAC, Cunha GM, Smorodinsky E et al (2015) Diagnostic accuracy of preoperative gadoxetic acid-enhanced 3-T MR imaging for malignant liver lesions by using ex vivo MR imaging-matched pathologic findings as the reference standard. Radiology 276:775–786CrossRef

14.

Hosseini-Nik H, Fischer SE, Moulton C-AE et al (2016) Diffusion-weighted and hepatobiliary phase gadoxetic acid-enhanced quantitative MR imaging for identification of complete pathologic response in colorectal liver metastases after preoperative chemotherapy. Abdom Radiol (NY) 41:231–238CrossRef

15.

Koh D-M, Collins DJ, Wallace T, Chau I, Riddell AM (2012) Combining diffusion-weighted MRI with Gd-EOB-DTPA-enhanced MRI improves the detection of colorectal liver metastases. Br J Radiol 85:980–989CrossRef

16.

Chung W-S, Kim M-J, Chung YE et al (2011) Comparison of gadoxetic acid-enhanced dynamic imaging and diffusion-weighted imaging for the preoperative evaluation of colorectal liver metastases. J Magn Reson Imaging 34:345–353CrossRef

17.

Vilgrain V, Esvan M, Ronot M, Caumont-Prim A, Aubé C, Chatellier G (2016) A meta-analysis of diffusion-weighted and gadoxetic acid-enhanced MR imaging for the detection of liver metastases. Eur Radiol 26:4595–4615CrossRef

18.

Zech CJ, Korpraphong P, Huppertz A et al (2014) Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases. Br J Surg 101:613–621CrossRef

19.

Neri E, Bali MA, Ba-Ssalamah A et al (2016) ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol 26:921–931CrossRef

20.

Canellas R, Patel MJ, Agarwal S, Sahani DV (2019) Lesion detection performance of an abbreviated gadoxetic acid–enhanced MRI protocol for colorectal liver metastasis surveillance. Eur Radiol 29:5852–5860CrossRef

21.

European Association for the Study of the Liver (EASL) (2016) EASL clinical practice guidelines on the management of benign liver tumours. J Hepatol 65:386–398CrossRef

22.

Tajima T, Akahane M, Takao H et al (2012) Detection of liver metastasis: is diffusion-weighted imaging needed in Gd-EOB-DTPA-enhanced MR imaging for evaluation of colorectal liver metastases? Jpn J Radiol 30:648–658CrossRef

23.

Oh J-W, Oh SN, Choi JI et al (2016) Does the gadoxetic acid-enhanced liver MRI impact on the treatment of patients with colorectal cancer? Comparison Study with ¹⁸F-FDG PET/CT. Biomed Res Int 2016:8412071PubMedPubMedCentral

24.

Colagrande S, Castellani A, Nardi C, Lorini C, Calistri L, Filippone A (2016) The role of diffusion-weighted imaging in the detection of hepatic metastases from colorectal cancer: a comparison with unenhanced and Gd-EOB-DTPA enhanced MRI. Eur J Radiol 85:1027–1034CrossRef

25.

Besa C, Lewis S, Pandharipande PV et al (2017) Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdom Radiol (NY) 42:179–190CrossRef

26.

Marks RM, Ryan A, Heba ER et al (2015) Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. AJR Am J Roentgenol 204:527–535CrossRef

27.

Hwang J, Kim YK, Kim JM, Lee WJ, Choi D, Hong SS (2014) Pretransplant diagnosis of hepatocellular carcinoma by gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging. Liver Transpl 20:1436–1446PubMed

28.

Vietti Violi N, Taouli B (2020) Abbreviated MRI for HCC surveillance: is it ready for clinical use? Eur Radiol. https://doi.org/10.1007/s00330-020-06904-8

29.

Whang S, Choi MH, Choi JI, Youn SY, Kim DH, Rha SE (2020) Comparison of diagnostic performance of non-contrast MRI and abbreviated MRI using gadoxetic acid in initially diagnosed hepatocellular carcinoma patients: a simulation study of surveillance for hepatocellular carcinomas. Eur Radiol. https://doi.org/10.1007/s00330-020-06754-4

30.

Vietti Violi N, Lewis S, Liao J et al (2020) Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening. Eur Radiol. https://doi.org/10.1007/s00330-020-07014-1

31.

Schwartz LH, Gandras EJ, Colangelo SM, Ercolani MC, Panicek DM (1999) Prevalence and importance of small hepatic lesions found at CT in patients with cancer. Radiology 210:71–74CrossRef

32.

Duran R, Ronot M, Kerbaol A, Beers BV, Vilgrain V (2014) Hepatic hemangiomas: factors associated with T2 shine-through effect on diffusion-weighted MR sequences. Eur J Radiol 83:468–478CrossRef

33.

Dioguardi Burgio M, Ronot M, Salvaggio G, Vilgrain V, Brancatelli G (2016) Imaging of hepatic focal nodular hyperplasia: pictorial review and diagnostic strategy. Semin Ultrasound CT MR 37:511–524CrossRef

34.

Kim JW, Lee CH, Park YS, Lee J, Kim KA (2019) Abbreviated gadoxetic acid–enhanced mri with second-shot arterial phase imaging for liver metastasis evaluation. Radiology: Imaging Cancer 1:e190006

35.

Lee D, Cho E-S, Kim DJ, Kim JH, Yu J-S, Chung J-J (2015) Validation of 10-minute delayed hepatocyte phase imaging with 30° flip angle in gadoxetic acid-enhanced MRI for the detection of liver metastasis. PLoS One 10:e0139863CrossRef

36.

Sofue K, Tsurusaki M, Tokue H, Arai Y, Sugimura K (2011) Gd-EOB-DTPA-enhanced 3.0T MR imaging: quantitative and qualitative comparison of hepatocyte-phase images obtained 10 min and 20 min after injection for the detection of liver metastases from colorectal carcinoma. Eur Radiol 21:2336–2343CrossRef

37.

Hayoz R, Vietti-Violi N, Duran R, Knebel JF, Ledoux JB, Dromain C (2020) The combination of hepatobiliary phase with Gd-EOB-DTPA and DWI is highly accurate for the detection and characterization of liver metastases from neuroendocrine tumor. Eur Radiol. https://doi.org/10.1007/s00330-020-06930-6

38.

Choi SA, Lee SS, Jung I-H, Kim HA, Byun JH, Lee M-G (2012) The effect of gadoxetic acid enhancement on lesion detection and characterisation using T₂ weighted imaging and diffusion weighted imaging of the liver. Br J Radiol 85:29–36CrossRef

39.

Chiu F-Y, Jao J-C, Chen C-Y et al (2005) Effect of intravenous gadolinium-DTPA on diffusion-weighted magnetic resonance images for evaluation of focal hepatic lesions. J Comput Assist Tomogr 29:176–180CrossRef

40.

Cieszanowski A, Podgórska J, Rosiak G et al (2016) Gd-EOB-DTPA-enhanced MR imaging of the liver: the effect on T2 relaxation times and apparent diffusion coefficient (ADC). Pol J Radiol 81:103–109CrossRef

41.

Chan VO, Das JP, Gerstenmaier JF et al (2012) Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist(®))-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre. Ir J Med Sci 181:499–509CrossRef

42.

Merkle EM, Zech CJ, Bartolozzi C et al (2016) Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol 26:674–682CrossRef

Title: The diagnostic performance of a simulated “short” gadoxetic acid-enhanced MRI protocol is similar to that of a conventional protocol for the detection of colorectal liver metastases
Authors: Camille Ghorra
Romain Pommier
Arthur Piveteau
Laura Rubbia-Brandt
Valérie Vilgrain
Sylvain Terraz
Maxime Ronot
Publication date: 01-04-2021
Publisher: Springer Berlin Heidelberg
Keywords: Magnetic Resonance Imaging
Magnetic Resonance Imaging
Metastasis
Colorectal Cancer
Colorectal Cancer
Published in: European Radiology / Issue 4/2021
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-020-07344-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The diagnostic performance of a simulated “short” gadoxetic acid-enhanced MRI protocol is similar to that of a conventional protocol for the detection of colorectal liver metastases

Abstract

Objectives

Methods

Results

Conclusion

Key Points

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusion

Key Points

Please log in to get access to this content

Other articles of this Issue 4/2021

Baseline bone marrow ADC value of diffusion-weighted MRI: a potential independent predictor for progression and death in patients with newly diagnosed multiple myeloma

Percutaneous transthoracic embolisation for massive haemoptysis secondary to peripheral pulmonary artery pseudoaneurysms

Association between spleen volume and the post-hepatectomy liver failure and overall survival of patients with hepatocellular carcinoma after resection

Intraoperative cone beam computed tomography is as reliable as conventional computed tomography for identification of pedicle screw breach in thoracolumbar spine surgery

Applicability of radiomics in interstitial lung disease associated with systemic sclerosis: proof of concept

Development of MR-based preoperative nomograms predicting DNA copy number subtype in lower grade gliomas with prognostic implication